In a move set to redefine the landscape of small-molecule drug development, AustinPx, a Texas-based contract development and manufacturing organization (CDMO), has announced an exclusive strategic agreement with Thermo Fisher Scientific’s Patheon division. The partnership aims to integrate AustinPx’s proprietary KinetiSol technology into Patheon’s global infrastructure, specifically at its sites in Bend, Oregon, and Cincinnati, Ohio.
This collaboration marks a significant pivot in the pharmaceutical industry’s approach to bioavailability, moving away from "last-resort" formulation strategies toward early-stage, predictive, and scalable manufacturing solutions.
The Core Challenge: The Global Solubility Crisis
The pharmaceutical industry currently faces a daunting reality: the majority of modern drug candidates are plagued by poor aqueous solubility. According to data cited in a 2023 review in the journal Life, approximately 40% of all currently commercialized drugs, and an overwhelming 70% to 90% of candidates currently in the development pipeline, exhibit poor solubility.
When a molecule suffers from low solubility, its bioavailability—the proportion of the drug that enters the circulation and is able to have an active effect—is severely compromised. This leads to a cascade of negative outcomes for drug sponsors, including the need for higher, potentially toxic doses, erratic patient responses, and in many cases, the abandonment of promising therapeutic candidates that simply cannot be formulated effectively.
Chronology: From Innovation to Industrial Scale
AustinPx has spent over 16 years refining KinetiSol, a fusion-based technology designed to create amorphous solid dispersions (ASD). Unlike traditional methods that rely on heat or solvent-based processing, KinetiSol utilizes high-shear, friction-based energy to create dispersions, allowing for the processing of molecules that are typically considered "undruggable" or difficult to manufacture.
- The Development Years: For over a decade, AustinPx acted as an innovator, focusing on proving the efficacy of KinetiSol for challenging molecules.
- The Growth Phase (2020–2024): Having supported more than 80 client programs, AustinPx solidified its position as a technical authority, successfully navigating complex technology transfers and commercial-scale installations.
- The Strategic Inflection Point (June 2026): AustinPx and Thermo Fisher Scientific announce a formal, exclusive third-party CDMO agreement. This agreement bridges the gap between AustinPx’s specialized early-phase expertise and the global, multi-site manufacturing footprint of Thermo Fisher’s Patheon division.
Integrating AI with Physical Manufacturing
A central pillar of this agreement is the integration of KinetiSol into Patheon’s "Quadrant 2" platform. This proprietary system leverages artificial intelligence and machine learning (AI/ML) to predict optimal formulations long before a physical prototype is created in the lab.
By feeding KinetiSol-specific process data into the Quadrant 2 AI models, the partnership creates a virtuous cycle. As the dataset grows, the predictive power of the platform increases, allowing formulation scientists to:
- Conserve limited API: Minimize the amount of expensive active pharmaceutical ingredient used in early-stage testing.
- Avoid Low-Value Experiments: Use predictive modeling to bypass pathways that are mathematically unlikely to succeed.
- Accelerate Timelines: Move from computational prediction to physical prototyping with a significantly higher degree of confidence.
Official Perspective: Q&A with AustinPx CEO Elizabeth Hickman
In an exclusive interview, AustinPx CEO Elizabeth Hickman addressed the implications of this partnership for the broader drug development community.
On the Nature of the "Exclusive" Agreement
"We are excited to partner with Thermo Fisher Scientific to expand access to our KinetiSol technology," Hickman stated. "While Thermo is our exclusive third-party CDMO for offering early-phase KinetiSol development on the Formulator scale, AustinPx remains the inventor, technology owner, and process expert. We continue to offer these capabilities directly to our clients, ensuring that our 16-plus years of experience remain at the heart of every program."
On the "Confidence Gap" in Late-Stage Development
Hickman emphasized that the biggest barrier to adopting novel formulation technologies is the regulatory and logistical hurdle of moving to commercial scale. "Sponsors are understandably cautious," she noted. "They don’t want to build a program around an enabling technology unless they see a clear, de-risked path to Phase 3 and commercial manufacturing. This agreement provides that secondary access point, giving sponsors the commercial optionality they require to commit to KinetiSol early in the pipeline."
Why KinetiSol Over Spray Drying or HME?
When asked how formulation scientists should choose between KinetiSol, spray drying, and hot-melt extrusion (HME), Hickman explained that the decision tree should be driven by the molecule’s specific physical characteristics.
"Spray drying is limited by solvent compatibility, and HME is limited by thermal sensitivity," she observed. "KinetiSol shines when a molecule is thermally labile, has a high melting point, or is insoluble in standard organic solvents. It is the tool of choice for complex, multi-component ASD systems that other technologies simply cannot touch."
Implications for the Future of Drug Discovery
The collaboration between AustinPx and Thermo Fisher Scientific signals a maturation of the CDMO market. Several key implications emerge for the pharmaceutical sector:
1. The Shift Toward "First-Choice" Technology
Historically, KinetiSol was viewed as a "rescue" technology—a solution to be deployed only after spray drying or HME failed. The current partnership aims to flip this dynamic. By providing a clear, global path for commercialization via Thermo Fisher, AustinPx is positioning KinetiSol as a "first-choice" strategy, which could significantly reduce the time and capital wasted on failed formulation attempts.
2. Standardizing the "Green" Formulation
As the pharmaceutical industry faces increasing pressure to reduce its environmental footprint, KinetiSol offers a distinct advantage. Because it avoids the massive solvent usage associated with spray drying, it aligns with broader industry goals regarding sustainability and "green" chemistry. The standardization of this technology within a global network like Patheon may well set a new industry benchmark for sustainable manufacturing.
3. De-risking the Supply Chain
For large-scale pharma companies and emerging biotechs alike, the ability to rely on a proven, multi-site network for late-stage manufacturing is a powerful incentive. By integrating KinetiSol into the Patheon network, sponsors gain access to a robust, audited, and compliant supply chain that can accommodate their molecules from the first milligram of development to the final commercial batch.
4. Competitive Dynamics in Formulation Science
This partnership also forces a re-evaluation of the competitive landscape. With AI-driven predictive modeling (Quadrant 2) combined with proprietary, high-performance manufacturing (KinetiSol), the threshold for entry into the "difficult-to-formulate" market has been raised. Other CDMOs may now face pressure to either develop their own proprietary enabling technologies or seek similar partnerships to maintain parity.
Conclusion: A New Era for Challenging Molecules
The agreement between AustinPx and Thermo Fisher Scientific is more than a simple business contract; it is a strategic alignment of technology and scale. By removing the perceived risks associated with scaling novel amorphous dispersion technologies, the partnership effectively democratizes access to high-performance formulation science.
For the drug developer, the message is clear: the constraints of poor solubility are no longer a terminal diagnosis for a drug candidate. With the right predictive tools and a clear, scalable manufacturing path, the industry is now better equipped than ever to bring complex, life-saving therapies to the patients who need them most. As this collaboration unfolds, the focus will undoubtedly shift to the first wave of commercial products to emerge from this integrated ecosystem, potentially ushering in a new era of efficiency in pharmaceutical development.
About the Author
